Severity of Illness Index

"Severity of Illness Index" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.

Descriptor ID	D012720
MeSH Number(s)	E05.318.308.980.438.475.456.500 N05.715.360.300.800.438.375.364.500 N06.850.520.308.980.438.475.364.500
Concept/Terms	Severity of Illness Index Severity of Illness Index Illness Index Severities Illness Index Severity Index Severities, Illness Index Severity, Illness

Below are MeSH descriptors whose meaning is more general than "Severity of Illness Index".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Epidemiologic Methods [E05.318]
Data Collection [E05.318.308]
Surveys and Questionnaires [E05.318.308.980]
Health Surveys [E05.318.308.980.438]
Health Status Indicators [E05.318.308.980.438.475]
Patient Acuity [E05.318.308.980.438.475.456]
Severity of Illness Index [E05.318.308.980.438.475.456.500]
Health Care [N]
Health Care Quality, Access, and Evaluation [N05]
Quality of Health Care [N05.715]
Health Care Evaluation Mechanisms [N05.715.360]
Data Collection [N05.715.360.300]
Surveys and Questionnaires [N05.715.360.300.800]
Health Surveys [N05.715.360.300.800.438]
Health Status Indicators [N05.715.360.300.800.438.375]
Patient Acuity [N05.715.360.300.800.438.375.364]
Severity of Illness Index [N05.715.360.300.800.438.375.364.500]
Environment and Public Health [N06]
Public Health [N06.850]
Epidemiologic Methods [N06.850.520]
Data Collection [N06.850.520.308]
Surveys and Questionnaires [N06.850.520.308.980]
Health Surveys [N06.850.520.308.980.438]
Health Status Indicators [N06.850.520.308.980.438.475]
Patient Acuity [N06.850.520.308.980.438.475.364]
Severity of Illness Index [N06.850.520.308.980.438.475.364.500]

Below are MeSH descriptors whose meaning is related to "Severity of Illness Index".

Below are MeSH descriptors whose meaning is more specific than "Severity of Illness Index".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Severity of Illness Index" by people in this website by year, and whether "Severity of Illness Index" was a major or minor topic of these publications.

Bar chart showing 1239 publications over 31 distinct years, with a maximum of 80 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	4	4	8
1996	7	8	15
1997	0	12	12
1998	1	8	9
1999	2	18	20
2000	0	16	16
2001	2	15	17
2002	1	24	25
2003	1	32	33
2004	1	27	28
2005	2	31	33
2006	0	44	44
2007	3	42	45
2008	3	60	63
2009	10	44	54
2010	6	46	52
2011	5	45	50
2012	8	56	64
2013	12	56	68
2014	1	51	52
2015	10	69	79
2016	7	66	73
2017	6	74	80
2018	5	46	51
2019	3	65	68
2020	5	61	66
2021	3	30	33
2022	0	16	16
2023	0	17	17
2024	8	17	25
2025	0	23	23

Below are the most recent publications written about "Severity of Illness Index" by people in Profiles.

Shah N, Katragkou A, Fortin O, Tomatis Souverbielle C, Santos Oren M, Sheth A, Calardo S, Hauger SB, Angelis D, Gagliardo C, Solaiman A, Erdem G, Harik N, Mulkey SB, Downey R, Ansusinha E, Chalak L, Chiu S, Di Pentima MC, S?nchez PJ, Teran PR. Predicting Severe Short-Term Neurologic Outcomes in Human Parechovirus Meningoencephalitis. Pediatrics. 2025 Oct 01; 156(4).

View in: PubMed
Lebwohl M, Gooderham MJ, Warren RB, Tha?i D, Foley P, Gottlieb AB, Torres T, Popmihajlov Z, Jou YM, Linaberry M, Daamen C, Griffiths CEM. Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clin Exp Dermatol. 2025 Sep 25; 50(10):2030-2036.

View in: PubMed
Ekuban FA, Gripshover TC, Ames P, Biswas K, Bolatimi OE, Abramson J, Iyer M, Luo J, Ekuban A, Hwang JY, Park JW, Banerjee M, Watson WH, Wahlang B, Bello D, Schlezinger JJ, McClain CJ, Cave MC. Perfluorooctane sulfonate exposure and alcohol-associated liver disease severity in a mouse chronic-binge ethanol feeding model. Toxicol Sci. 2025 Aug 01; 206(2):388-408.

View in: PubMed
Lo SB, Shin J, Holtze ME, Post KE, Eche-Ugwu IJ, Temel JS, Cooley ME, Greer JA. Characterization of multidimensional dyspnea in advanced lung cancer with moderate to severe dyspnea-related functional impairment: a latent profile analysis. Support Care Cancer. 2025 Jul 18; 33(8):700.

View in: PubMed
Tripathi S, McGarvey J, Montgomery V, Gharpure VP, Kashyap R, Walkey A, Bansal V, Boman K, Kumar VK, Kissoon N. Prevalence of Sepsis as Defined by Phoenix Sepsis Definition Among Children With COVID-19. Hosp Pediatr. 2025 Jul 01; 15(7):554-562.

View in: PubMed
Ezzedine K, Parsad D, Harris JE, van Geel N, Gardner J, Bibeau K, Gao J, Ren H, Hamzavi IH. Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey. J Dermatolog Treat. 2025 Dec; 36(1):2504082.

View in: PubMed
Krishna MM, Joseph M, Ezenna C, Pereira V, Rossi R, Akman Z, Rubens M, Mahadevan VS, Nanna MG, Goldsweig AM. TAVR vs. SAVR for severe aortic stenosis in the low and intermediate surgical risk population: An updated meta-analysis, meta-regression, and trial sequential analysis. Cardiovasc Revasc Med. 2025 Oct; 79:78-89.

View in: PubMed
Tambiah J, Kennedy S, Swearingen C, McAlindon T, Yazici Y. Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials. Rheumatology (Oxford). 2025 May 01; 64(5):2583-2590.

View in: PubMed
Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025 May 01; 392(17):1710-1720.

View in: PubMed
Doma M, Huang W, Hernandez S, Fatima SR, Lingamsetty S, Kritya M, Hemdanieh M, Naji Z, Gewehr DM, Martignoni FV, Goldsweig AM. Immediate transcatheter aortic valve replacement versus temporizing balloon aortic valvuloplasty in severe aortic stenosis: A systematic review and meta-analysis immediate TAVR vs. temporizing BAV. Cardiovasc Revasc Med. 2025 Aug; 77:112-121.

View in: PubMed

People

Explore

Similar Concepts

Top Journals